CIME 2025: Pharmacologic presbyopia correction provides new hope for flexibility for patients

Commentary
Video

At the Controversies in Modern Eye Care meeting in Los Angeles, California, which took place May 4, 2025, Jacob Lang, OD, FAAO, director of dry eye services at Associated Eye Care in the Twin Cities metro area of Minnesota, shared his perspective on one of the most exciting advancements in vision care: pharmacologic correction for presbyopia.

A new frontier in presbyopia management

Key takeaways for optometrists:

  • Pharmacologic presbyopia treatments offer patients increased flexibility and lifestyle freedom.
  • Motivation and expectation management are crucial in identifying good candidates.
  • Provider education is a significant barrier—many ODs remain unaware of new options.
  • Comprehensive ocular care must remain central when prescribing presbyopia drops.

According to Lang, pharmacologic options for presbyopia represent a long-awaited shift in how eye care professionals can help patients manage age-related near vision loss. What excites him most is the flexibility these therapies offer. “Pharmacologic correction gives patients the freedom to use it when they need it," he explained. “It’s about enabling lifestyle choices and offering convenience in the busy presbyopic years.”

This shift isn’t just about avoiding reading glasses; it's about empowering patients with control over their vision, particularly those who lead dynamic personal and professional lives.

Identifying ideal candidates

Lang emphasizes motivation as the key driver when choosing candidates for pharmacologic treatment. “We're looking for patients who are motivated to do something different,” he said. These patients often want more freedom in their daily routines and are willing to try new options to achieve it. The ideal candidate is one who values the flexibility these therapies offer and has realistic expectations about their use.

Breaking down barriers

Lang also highlighted a surprising barrier: provider awareness. “One of the biggest challenges is that many doctors aren’t familiar with the available pharmacologic options,” he said. As a result, patients may not even be offered these treatments. For Lang, continued professional education and openness to innovation are critical. “We need to embrace new tools and understand how they can benefit our patients.”

Preserving comprehensive ocular health

Finally, Lang reminded attendees that any pharmacologic intervention must be grounded in sound clinical judgment. “We have to treat the entire eye, front to back. From ocular surface to retina, we’re still the doctor.” He stressed that presbyopia drops are, after all, pharmaceuticals and should be managed with the same diligence as any other ocular therapy.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Karl Stonecipher ASCRS 2025
© 2025 MJH Life Sciences

All rights reserved.